Focused On-demand Library for Ubiquitin carboxyl-terminal hydrolase isozyme L3

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.

The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.

The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.

We employ our advanced, specialised process to create targeted libraries for enzymes.

Fig. 1. The sreening workflow of Receptor.AI

It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.

Our library stands out due to several important features:

The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.
Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.
Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.
Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.

partner

Reaxense

upacc

P15374

UPID:

UCHL3_HUMAN

Alternative names:

Ubiquitin thioesterase L3

Alternative UPACC:

P15374; B2R970; Q5TBK8; Q6IBE9

Background:

Ubiquitin carboxyl-terminal hydrolase isozyme L3, also known as Ubiquitin thioesterase L3, plays a pivotal role in cellular processes by controlling ubiquitin levels. It processes ubiquitin precursors and ubiquitinated proteins, favoring 'Lys-48'-linked ubiquitin chains. This enzyme is crucial for the regulation of insulin signaling, adipogenesis, and the maintenance of retinal, skeletal muscle, and germ cells. It also has implications in memory function.

Therapeutic significance:

Understanding the role of Ubiquitin carboxyl-terminal hydrolase isozyme L3 could open doors to potential therapeutic strategies.